NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors
- Determine the safety of fluorothymidine F 18 for visual and dynamic brain tumor images
in patients with glial neoplasms.
- Determine, preliminarily, the efficacy of this drug.
- Compare, preliminarily, the efficacy of this drug to fludeoxyglucose F 18 in
differentiating tumor recurrence from radiation necrosis.
- Determine the optimal time to image post injection of this drug.
OUTLINE: This is a pilot, nonrandomized study.
Patients receive fluorothymidine F 18 IV over 1 minute and then undergo positron emission
tomography (PET) scanning of the brain over 2 hours.
After completion of the PET scan, patients are followed for at least 1 month.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Alexander M. Spence, MD
University of Washington
United States: Federal Government
|University Cancer Center at University of Washington Medical Center||Seattle, Washington 98195|